Search Grant Opportunities

Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

ID: RFA-CA-24-024 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to provide the infrastructure for early-phase cancer prevention clinical trials through the Cancer Prevention Clinical Trials Network (CP-CTNet), DCP's main mechanism for early clinical development of cancer preventive interventions. The phase 0-2 trials performed through CP-CTNet evaluate biologic effects of interventions and determine clinically relevant correlates, with the ultimate goal of advancing their further development for cancer prevention. The research network will develop multiple cancer prevention clinical trials targeting cancers arising in various organ sites, including collaborative studies across the Network, using the UG1 cooperative agreement funding mechanisms. This NOFO relates to the performance sites that will plan and perform clinical trials.
Background
The National Cancer Institute (NCI) is issuing this Notice of Funding Opportunity (NOFO) to support the Cancer Prevention Clinical Trials Network (CP-CTNet). This initiative aims to provide infrastructure for early-phase cancer prevention clinical trials. The goal is to evaluate biologic effects of interventions and determine clinically relevant correlates to advance their development for cancer prevention. The CP-CTNet will focus on multiple cancer prevention clinical trials targeting various organ sites, utilizing UG1 cooperative agreement funding mechanisms.

Grant Details
The CP-CTNet Sites will be responsible for the design, conduct, and reporting of early phase clinical trials (phase 0-II) that assess the safety, tolerability, and cancer preventive potential of various agents and interventions. Specific tasks include:
1. Designing and conducting early phase clinical trials targeting relevant pathways in carcinogenesis.
2. Characterizing biological effects of agents on molecular targets and correlating these with clinical endpoints.
3. Developing insights into mechanisms of cancer prevention and identifying novel response markers.
4. Managing study operations, including quality assurance and compliance with regulations.
5. Conducting a minimum of 1-3 new clinical trials per year with participant accrual targets ranging from 10-40 participants annually depending on site status.
6. Engaging in cross-network trials to facilitate collaborative research efforts.

Eligibility Requirements
Eligible organizations include higher education institutions (public or private), nonprofits, federal agencies, U.S. territories, and foreign organizations are not eligible to apply. Institutions are encouraged to include diverse applicants from underrepresented groups in their proposals.

Period of Performance
The project period will span six years, beginning in FY 2025.

Grant Value
NCI intends to commit $8,750,000 each year for six years, supporting approximately five awards for CP-CTNet Sites. Each award may request up to $1,375,000 in direct costs annually.

Place of Performance
The specific geographic locations for the performance of the grant have not been detailed but will involve multiple institutions collaborating within the CP-CTNet framework.

Overview

Category of Funding
Education
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 8/12/24 the National Institutes of Health posted grant opportunity RFA-CA-24-024 for Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required). The grant will be issued under grant program 93.393 Cancer Cause and Prevention Research.

Timing

Posted Date
Aug. 12, 2024, 12:00 a.m. EDT
Closing Date
Oct. 31, 2024, 12:00 a.m. EDT Past Due
Last Updated
Aug. 12, 2024, 2:02 p.m. EDT
Version
1
Archive Date
Dec. 6, 2024

Eligibility

Eligible Applicants
City or township governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
State governments
For profit organizations other than small businesses
Private institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Contact Phone
(301) 402-2541
Additional Information
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-024.html

Documents

Posted documents for RFA-CA-24-024

Grant Awards

Grants awarded through RFA-CA-24-024

Incumbent or Similar Grants

Grants similar to RFA-CA-24-024

Similar Active Opportunities

Open grant opportunities similar to RFA-CA-24-024